Alzinova AB

ALZ · Nasdaq Stockholm · Healthcare

0.40SEK −1.7%last day

Price as of 2 October 2026

The price over the past year, with dividends: −64.3%

Performance

1 month

−52.9%

1 year

−64.3%

3 years, per year

−48.9%

5 years, per year

−43.4%

Largest fall, 3 years

−91.1%

Below the peak now

−98.5%

Volatility, 1 year

237.8%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

0.4

Dividend yield

0.0%

Return on equity

−15.6%

Net margin

−151.3%

Market value

6 m USD

Quality, value and trend

Where Alzinova stands against every Nordic stock today. 100 is best.

Quality87

Profitability and a sound balance sheet over time. Better than 87% of Nordic stocks.

Value30

The price measured against earnings, assets and cash flow. Better than 30% of Nordic stocks.

Trend7

The price development over the past year. Better than 7% of Nordic stocks.

Combined31

Quality, value and trend together. Better than 31% of Nordic stocks.

About Alzinova

Alzinova AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 7 employees.

Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis